Elena Sanz Pascual

A two-part study of ZX008 in children and adults with Lennox-Gastaut Syndrome (LGS); Part 1: a randomized, double-blind, placebo-controlled trial of two fixed doses of ZX008 (Fenfluramine Hydrochloride) oral solution as adjunctive therapy for seizures in children and adults with LGS, followed by part 2: an open-label extension to assess long-term safety of ZX008 in children and adults with LGS. Study number: ZX008-1601

An open-label extension trial to assess the long-term safety of ZX008 (Fenfluramine Hydrochloride) oral solution as an adjunctive therapy in children and young adults with Dravet Syndrome. Study number: ZX008-1503

A multicenter, randomized, double-blind, parallel group, placebo-controlled trial of two fixed doses of ZX00 (Fenfluramine Hydrocholoride) oral solution as an adjunctive therapy in children and young adults with Dravet Syndrome. Study number: ZX008-1502

A multicenter, 2-cohort trial to first assess the pharmacokinetic and safety profile of a single dose of ZX008 (Fenfluramine Hydrochloride) oral solution when added to standard of care (cohort1), followed by a randomized, double-blind, placebo-controlled parallel group evaluation of the efficacy, safety and tolerability of ZX008 as adjunctive antiepileptic therapy to Stiripentol treatment in children and young adults with Dravet Syndrome (Cohort 2). Study number: ZX008-1504

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients with Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome, 245208, Site 1101. ZX008-1900